96 related articles for article (PubMed ID: 25372020)
1. Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer.
Cummings CT; Linger RM; Cohen RA; Sather S; Kirkpatrick GD; Davies KD; DeRyckere D; Earp HS; Graham DK
Oncotarget; 2014 Nov; 5(21):10434-45. PubMed ID: 25372020
[TBL] [Abstract][Full Text] [Related]
2. UNC1062, a new and potent Mer inhibitor.
Liu J; Zhang W; Stashko MA; Deryckere D; Cummings CT; Hunter D; Yang C; Jayakody CN; Cheng N; Simpson C; Norris-Drouin J; Sather S; Kireev D; Janzen WP; Earp HS; Graham DK; Frye SV; Wang X
Eur J Med Chem; 2013 Jul; 65():83-93. PubMed ID: 23693152
[TBL] [Abstract][Full Text] [Related]
3. Pathways and therapeutic targets in melanoma.
Shtivelman E; Davies MQ; Hwu P; Yang J; Lotem M; Oren M; Flaherty KT; Fisher DE
Oncotarget; 2014 Apr; 5(7):1701-52. PubMed ID: 24743024
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis of cancer cells is triggered by selective crosslinking and inhibition of receptor tyrosine kinases.
Wang K; Wang X; Hou Y; Zhou H; Mai K; He G
Commun Biol; 2019; 2():231. PubMed ID: 31263775
[TBL] [Abstract][Full Text] [Related]
5. Regulation of brain endothelial cell physiology by the TAM receptor tyrosine kinase Mer.
Happonen KE; Burrola PG; Lemke G
Commun Biol; 2023 Sep; 6(1):916. PubMed ID: 37673933
[TBL] [Abstract][Full Text] [Related]
6. Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status.
Cummings CT; Zhang W; Davies KD; Kirkpatrick GD; Zhang D; DeRyckere D; Wang X; Frye SV; Earp HS; Graham DK
Mol Cancer Ther; 2015 Sep; 14(9):2014-22. PubMed ID: 26162689
[TBL] [Abstract][Full Text] [Related]
7. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer.
Graham DK; DeRyckere D; Davies KD; Earp HS
Nat Rev Cancer; 2014 Dec; 14(12):769-85. PubMed ID: 25568918
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia.
Lee-Sherick AB; Zhang W; Menachof KK; Hill AA; Rinella S; Kirkpatrick G; Page LS; Stashko MA; Jordan CT; Wei Q; Liu J; Zhang D; DeRyckere D; Wang X; Frye S; Earp HS; Graham DK
Oncotarget; 2015 Mar; 6(9):6722-36. PubMed ID: 25762638
[TBL] [Abstract][Full Text] [Related]
9. TAM receptor signaling in immune homeostasis.
Rothlin CV; Carrera-Silva EA; Bosurgi L; Ghosh S
Annu Rev Immunol; 2015; 33():355-91. PubMed ID: 25594431
[TBL] [Abstract][Full Text] [Related]
10. Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data.
Ryall KA; Shin J; Yoo M; Hinz TK; Kim J; Kang J; Heasley LE; Tan AC
Bioinformatics; 2015 Dec; 31(23):3799-806. PubMed ID: 26206305
[TBL] [Abstract][Full Text] [Related]
11. XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer.
Morton JJ; Bird G; Keysar SB; Astling DP; Lyons TR; Anderson RT; Glogowska MJ; Estes P; Eagles JR; Le PN; Gan G; McGettigan B; Fernandez P; Padilla-Just N; Varella-Garcia M; Song JI; Bowles DW; Schedin P; Tan AC; Roop DR; Wang XJ; Refaeli Y; Jimeno A
Oncogene; 2016 Jan; 35(3):290-300. PubMed ID: 25893296
[TBL] [Abstract][Full Text] [Related]
12. Grape seed extract targets mitochondrial electron transport chain complex III and induces oxidative and metabolic stress leading to cytoprotective autophagy and apoptotic death in human head and neck cancer cells.
Shrotriya S; Deep G; Lopert P; Patel M; Agarwal R; Agarwal C
Mol Carcinog; 2015 Dec; 54(12):1734-47. PubMed ID: 25557495
[TBL] [Abstract][Full Text] [Related]
13. The PPAR-γ antagonist GW9662 elicits differentiation of M2c-like cells and upregulation of the MerTK/Gas6 axis: a key role for PPAR-γ in human macrophage polarization.
Zizzo G; Cohen PL
J Inflamm (Lond); 2015; 12():36. PubMed ID: 25972766
[TBL] [Abstract][Full Text] [Related]
14. Mer tyrosine kinase promotes the survival of t(1;19)-positive acute lymphoblastic leukemia (ALL) in the central nervous system (CNS).
Krause S; Pfeiffer C; Strube S; Alsadeq A; Fedders H; Vokuhl C; Loges S; Waizenegger J; Ben-Batalla I; Cario G; Möricke A; Stanulla M; Schrappe M; Schewe DM
Blood; 2015 Jan; 125(5):820-30. PubMed ID: 25428221
[TBL] [Abstract][Full Text] [Related]
15. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.
Lee-Sherick AB; Jacobsen KM; Henry CJ; Huey MG; Parker RE; Page LS; Hill AA; Wang X; Frye SV; Earp HS; Jordan CT; DeRyckere D; Graham DK
JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385715
[TBL] [Abstract][Full Text] [Related]
16. Phosphatidylserine Sensing by TAM Receptors Regulates AKT-Dependent Chemoresistance and PD-L1 Expression.
Kasikara C; Kumar S; Kimani S; Tsou WI; Geng K; Davra V; Sriram G; Devoe C; Nguyen KN; Antes A; Krantz A; Rymarczyk G; Wilczynski A; Empig C; Freimark B; Gray M; Schlunegger K; Hutchins J; Kotenko SV; Birge RB
Mol Cancer Res; 2017 Jun; 15(6):753-764. PubMed ID: 28184013
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy.
Hu Y; Revenko A; Barsoumian H; Bertolet G; Fowlkes NW; Maazi H; Green MM; He K; Sezen D; Voss TA; Leyton CSK; Masrorpour F; Rafiq Z; Puebla-Osorio N; Leuschner C; MacLeod R; Cortez MA; Welsh JW
J Exp Clin Cancer Res; 2024 Mar; 43(1):70. PubMed ID: 38443968
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
